bosutinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 4359 380843-75-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • WAY-173606
  • bosutinib
  • bosulif
  • bosutinib monohydrate
  • bosutinib hydrate
  • SKI-606
  • SKI 606
a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases
  • Molecular weight: 530.45
  • Formula: C26H29Cl2N5O3
  • CLOGP: 4.94
  • LIPINSKI: 1
  • HAC: 8
  • HDO: 1
  • TPSA: 82.88
  • ALOGS: -4.75
  • ROTB: 9
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 18 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 3.411 Moderate 0.73
caco2-efflux Caco-2 efflux ratio (BA/AB) 3.776 Moderate 0.73
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 14.125 10^-6 cm/s Moderate 0.73
dh-clint Dog hepatocyte intrinsic clearance 16.181 uL/min/10^6 cells Moderate 0.73
dppb Dog plasma protein binding (% unbound) 3.790 % Moderate 0.73
fcs-ppb Fetal calf serum protein binding (% unbound) 12.100 % Moderate 0.73
herg hERG pIC50 5.744 pIC50 Moderate 0.73
hh-clint Human hepatocyte intrinsic clearance 5.848 uL/min/10^6 cells Moderate 0.73
hlm-clint Human liver microsomal intrinsic clearance 84.140 uL/min/mg protein Moderate 0.73
hppb Human plasma protein binding (% unbound) 2.360 % Moderate 0.73
kinase-safety-class AAK1,ABL1,ABL2,ACVR1B,ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BLK,BMX,BRAF,BTK,CAMK2A,CAMK2B,CAMK2D,CAMK2G,CDK1,CDK14,CDK16,CDK19,CDK2,CDK4,CDK5,CDK7,CDK9,CHEK1,CLK2,CLK4,CSF1R,CSK,DDR1,DYRK1B,EGFR,EIF2AK3,EPHA2,EPHB1,EPHB3,EPHB4,ERBB2,ERBB4,FGFR1,FGFR4,FLT3,FLT4,FYN,GAK,GRK1,GRK2,GSK3A,GSK3B,HASPIN,IGF1R,IKBKB,INSR,INSRR,IRAK1,IRAK3,IRAK4,ITK,JAK1,JAK2,JAK3,KDR,KIT,LCK,LRRK2,LYN,MAP2K1,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K19,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP3K9,MAP4K1,MAP4K2,MAP4K3,MAP4K5,MAPK1,MAPK10,MAPK12,MAPK14,MAPK3,MAPK7,MAPK8,MAPK9,MARK1,MARK2,MARK4,MET,MINK1,MST1R,MTOR,NTRK1,NTRK2,NUAK1,PAK1,PAK2,PAK4,PDGFRB,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CG,PIM1,PIM2,PIM3,PLK1,PLK2,PLK3,PLK4,PRKAA1,PRKAA2,PRKACA,PRKCD,PRKCI,PRKCZ,PRKDC,PTK2,PTK6,RET,RIPK3,ROCK1,ROCK2,RPS6KA1,SIK2,SIK3,SRC,STK10,STK17A,STK33,STK4,SYK,TBK1,TEK,TNIK,TTK,TYRO3,ULK1,ULK2,YES1,ZAP70 156
kinase-selectivity-class ABL2,ACVR1B,ACVR2A,ACVR2B,ALK,AURKA,AURKB,AXL,BLK,BMX,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK9,CHEK1,CSF1R,CSK,DDR1,EGFR,EIF2AK3,EPHA2,EPHB4,ERBB2,ERBB4,FLT3,FYN,GAK,INSR,IRAK1,IRAK3,IRAK4,JAK1,JAK2,KIT,LCK,LYN,MAP2K1,MAP3K10,MAP3K11,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAP4K5,MAPK1,MAPK12,MAPK7,MARK4,MET,MINK1,MTOR,NTRK1,NUAK1,PAK1,PAK2,PAK4,PDGFRB,PDK4,PRKCD,RET,RIPK3,SIK2,SIK3,SRC,STK10,STK33,STK4,SYK,TEK,TNIK,TTK,TYRO3,ULK1,ULK2,YES1 77
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 12.853 Moderate 0.73
mh-clint Mouse hepatocyte intrinsic clearance 28.576 Moderate 0.73
mppb Mouse plasma protein binding (% unbound) 2.620 Moderate 0.73
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 41.687 Moderate 0.73
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 7.680 % Moderate 0.73
rh-clint Rat hepatocyte intrinsic clearance 24.434 uL/min/10^6 cells Moderate 0.73
rh-fuinc Rat hepatocyte fraction unbound in incubation 11.390 % Moderate 0.73
rppb Rat plasma protein binding (% unbound) 2.600 % Moderate 0.73
solubility-dd Solubility at pH 7.4 in DMSO 14.791 uM Moderate 0.73

Approvals:

DateAgencyCompanyOrphan
Sept. 26, 2014 PMDA Pfizer Japan Inc
Sept. 4, 2012 FDA WYETH PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 872.85 24.92 688 7333 938502 89681924
Nausea 281.62 24.92 411 7610 1109905 89510521
Pleural effusion 197.49 24.92 123 7898 111868 90508558
Neoplasm progression 183.57 24.92 86 7935 44400 90576026
Cytogenetic analysis abnormal 150.46 24.92 31 7990 979 90619447
Drug resistance 119.83 24.92 57 7964 30392 90590034
Philadelphia chromosome positive 115.11 24.92 22 7999 468 90619958
Vomiting 102.69 24.92 219 7802 788074 89832352
Blast crisis in myelogenous leukaemia 90.96 24.92 19 8002 642 90619784
Rash 75.98 24.92 196 7825 795904 89824522
Cytopenia 66.60 24.92 32 7989 17417 90603009
Fatigue 64.93 24.92 236 7785 1153787 89466639
Pericardial effusion 58.66 24.92 38 7983 36795 90583631
Abdominal pain 47.85 24.92 107 7914 395614 90224812
Bone pain 47.03 24.92 41 7980 61942 90558484
Haematotoxicity 44.86 24.92 22 7999 12513 90607913
Graft versus host disease in eye 44.75 24.92 8 8013 116 90620310
Pulmonary oedema 43.00 24.92 39 7982 62041 90558385
Drug intolerance 39.22 24.92 107 7914 447484 90172942
Abdominal pain upper 36.91 24.92 87 7934 332587 90287839
Capillary leak syndrome 34.96 24.92 12 8009 2755 90617671
Second primary malignancy 33.55 24.92 17 8004 10361 90610065
Platelet count abnormal 33.19 24.92 13 8008 4322 90616104
Illness 32.24 24.92 38 7983 81931 90538495
Death 30.34 24.92 99 7922 456452 90163974
Fluid retention 30.04 24.92 38 7983 88053 90532373
Constipation 26.50 24.92 69 7952 280326 90340100
Pancytopenia 24.99 24.92 41 7980 120222 90500204

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 665.98 24.32 569 6520 460280 42153966
Pleural effusion 291.59 24.32 188 6901 96978 42517268
Neoplasm progression 265.00 24.32 118 6971 28882 42585364
Drug intolerance 153.06 24.32 118 6971 80306 42533940
Cytogenetic analysis abnormal 133.69 24.32 30 7059 745 42613501
Nausea 105.31 24.32 214 6875 396585 42217661
Philadelphia chromosome positive 95.39 24.32 22 7067 619 42613627
Drug resistance 84.82 24.32 59 7030 34189 42580057
Fatigue 79.81 24.32 203 6886 435438 42178808
Second primary malignancy 71.74 24.32 34 7055 9541 42604705
Abdominal discomfort 63.25 24.32 70 7019 75185 42539061
Rash 51.44 24.32 130 6959 276824 42337422
Blast crisis in myelogenous leukaemia 44.34 24.32 12 7077 654 42613592
Myopathy toxic 38.54 24.32 11 7078 730 42613516
Gene mutation identification test positive 34.86 24.32 8 7081 220 42614026
Fluid retention 34.78 24.32 34 7055 31585 42582661
Abdominal pain upper 33.76 24.32 54 7035 82555 42531691
Acquired gene mutation 30.35 24.32 11 7078 1569 42612677
Muscle disorder 29.63 24.32 13 7076 3051 42611195
Vomiting 28.42 24.32 109 6980 289614 42324632
Clonal evolution 27.55 24.32 6 7083 129 42614117
Therapy interrupted 26.49 24.32 25 7064 22225 42592021
Hepatotoxicity 25.71 24.32 26 7063 25141 42589105
Chronic myeloid leukaemia transformation 24.94 24.32 6 7083 203 42614043

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 1386.88 21.04 1115 12313 1138390 109437481
Pleural effusion 385.98 21.04 250 13178 177459 110398412
Neoplasm progression 364.86 21.04 171 13257 64424 110511447
Nausea 327.26 21.04 555 12873 1235135 109340736
Cytogenetic analysis abnormal 193.75 21.04 42 13386 1227 110574644
Philadelphia chromosome positive 172.86 21.04 36 13392 864 110575007
Fatigue 136.72 21.04 388 13040 1215570 109360301
Vomiting 105.34 21.04 294 13134 910381 109665490
Rash 98.80 21.04 269 13159 820695 109755176
Second primary malignancy 90.19 21.04 44 13384 18024 110557847
Drug resistance 72.88 21.04 58 13370 56316 110519555
Blast crisis in myelogenous leukaemia 67.01 21.04 17 13411 991 110574880
Death 63.01 21.04 207 13221 698662 109877209
Pulmonary oedema 59.33 21.04 67 13361 100592 110475279
Pericardial effusion 57.69 21.04 51 13377 57166 110518705
Abdominal pain 56.47 21.04 163 13265 512826 110063045
Abdominal pain upper 56.12 21.04 128 13300 348983 110226888
Bone pain 50.18 21.04 50 13378 65083 110510788
Fluid retention 47.63 21.04 58 13370 94249 110481622
Cytopenia 45.50 21.04 34 13394 30082 110545789
Illness 42.25 21.04 51 13377 82120 110493751
Acquired gene mutation 34.93 21.04 13 13415 2741 110573130
Constipation 34.87 21.04 109 13319 357677 110218194
Pulmonary arterial hypertension 34.77 21.04 30 13398 32538 110543333
Drug intolerance 33.51 21.04 117 13311 406395 110169476
Chylothorax 32.81 21.04 10 13418 1146 110574725
Graft versus host disease in eye 31.77 21.04 8 13420 452 110575419
Clonal evolution 31.06 21.04 7 13421 245 110575626
Chronic myeloid leukaemia transformation 29.33 21.04 7 13421 316 110575555
White blood cell count increased 28.55 21.04 46 13382 96796 110479075
Renal disorder 27.56 21.04 32 13396 49447 110526424
Myopathy toxic 27.38 21.04 9 13419 1316 110574555
Abdominal discomfort 27.12 21.04 107 13321 393751 110182120
Myalgia 26.68 21.04 73 13355 222308 110353563
Rheumatoid arthritis 25.94 21.04 3 13425 299610 110276261
Toxicity to various agents 25.91 21.04 13 13415 480542 110095329
Haematotoxicity 25.77 21.04 21 13407 21061 110554810
Drug ineffective 25.49 21.04 97 13331 1520443 109055428
Cardiac disorder 24.94 21.04 38 13390 76242 110499629
Cardiac failure 22.91 21.04 62 13366 187564 110388307
Product dose omission issue 22.61 21.04 88 13340 321694 110254177
Therapy cessation 21.69 21.04 27 13401 44830 110531041
Capillary leak syndrome 21.67 21.04 11 13417 4897 110570974
Muscle disorder 21.16 21.04 12 13416 6660 110569211

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EA04 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
BCR-ABL tyrosine kinase inhibitors
FDA MoA N0000020009 Bcr-Abl Tyrosine Kinase Inhibitors
MeSH PA D000092004 Tyrosine Kinase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:38637 tyrosine kinase inhibitor

Related Drugs by ATC class:

L01EA BCR-ABL tyrosine kinase inhibitors 5 drugs
asciminibdasatinibimatinibnilotinibponatinib

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Blastic phase chronic myeloid leukemia indication 413656006
Chronic phase chronic myeloid leukemia indication 413847001
Chronic Myelocytic Leukemia Accelerated Phase indication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.74 Basic
pKa2 6.69 Basic
pKa3 4.74 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 100MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL 7417148 Dec. 11, 2025 A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
EQ 100MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL 7417148 Dec. 11, 2025 A METHOD OF TREATING PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE PH+ CML, NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
EQ 100MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL 7417148 Dec. 11, 2025 A METHOD OF TREATING PATIENTS WITH ACCELERATED, OR BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY
EQ 400MG BASE BOSULIF PF PRISM CV N203341 Oct. 27, 2017 RX TABLET ORAL 7417148 Dec. 11, 2025 A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
EQ 400MG BASE BOSULIF PF PRISM CV N203341 Oct. 27, 2017 RX TABLET ORAL 7417148 Dec. 11, 2025 A METHOD OF TREATING PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE PH+ CML, NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
EQ 400MG BASE BOSULIF PF PRISM CV N203341 Oct. 27, 2017 RX TABLET ORAL 7417148 Dec. 11, 2025 A METHOD OF TREATING PATIENTS WITH ACCELERATED, OR BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY
EQ 500MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL 7417148 Dec. 11, 2025 A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
EQ 500MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL 7417148 Dec. 11, 2025 A METHOD OF TREATING PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE PH+ CML, NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
EQ 500MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL 7417148 Dec. 11, 2025 A METHOD OF TREATING PATIENTS WITH ACCELERATED, OR BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY
EQ 100MG BASE BOSULIF PF PRISM CV N217729 Sept. 26, 2023 RX CAPSULE ORAL 7417148 Dec. 11, 2025 A METHOD OF TREATING PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE PH+ CML, NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
EQ 100MG BASE BOSULIF PF PRISM CV N217729 Sept. 26, 2023 RX CAPSULE ORAL 7417148 Dec. 11, 2025 A METHOD OF TREATING PATIENTS WITH ACCELERATED, OR BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY
EQ 50MG BASE BOSULIF PF PRISM CV N217729 Sept. 26, 2023 RX CAPSULE ORAL 7417148 Dec. 11, 2025 A METHOD OF TREATING PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE PH+ CML, NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
EQ 50MG BASE BOSULIF PF PRISM CV N217729 Sept. 26, 2023 RX CAPSULE ORAL 7417148 Dec. 11, 2025 A METHOD OF TREATING PATIENTS WITH ACCELERATED, OR BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY
EQ 100MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL 11103497 Feb. 28, 2034 A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT 949T>C
EQ 100MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL 11103497 Feb. 28, 2034 A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT F317L
EQ 400MG BASE BOSULIF PF PRISM CV N203341 Oct. 27, 2017 RX TABLET ORAL 11103497 Feb. 28, 2034 A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT 949T>C
EQ 400MG BASE BOSULIF PF PRISM CV N203341 Oct. 27, 2017 RX TABLET ORAL 11103497 Feb. 28, 2034 A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT F317L
EQ 500MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL 11103497 Feb. 28, 2034 A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT 949T>C
EQ 500MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL 11103497 Feb. 28, 2034 A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT F317L
EQ 100MG BASE BOSULIF PF PRISM CV N217729 Sept. 26, 2023 RX CAPSULE ORAL 11103497 Feb. 28, 2034 A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT 949T>C
EQ 100MG BASE BOSULIF PF PRISM CV N217729 Sept. 26, 2023 RX CAPSULE ORAL 11103497 Feb. 28, 2034 A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT F317L
EQ 50MG BASE BOSULIF PF PRISM CV N217729 Sept. 26, 2023 RX CAPSULE ORAL 11103497 Feb. 28, 2034 A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT 949T>C
EQ 50MG BASE BOSULIF PF PRISM CV N217729 Sept. 26, 2023 RX CAPSULE ORAL 11103497 Feb. 28, 2034 A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT F317L

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 100MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL Sept. 26, 2026 FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML), NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
EQ 400MG BASE BOSULIF PF PRISM CV N203341 Oct. 27, 2017 RX TABLET ORAL Sept. 26, 2026 FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML), NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
EQ 500MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL Sept. 26, 2026 FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML), NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
EQ 100MG BASE BOSULIF PF PRISM CV N217729 Sept. 26, 2023 RX CAPSULE ORAL Sept. 26, 2026 NEW PRODUCT
EQ 50MG BASE BOSULIF PF PRISM CV N217729 Sept. 26, 2023 RX CAPSULE ORAL Sept. 26, 2026 NEW PRODUCT
EQ 100MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL March 26, 2027 PEDIATRIC EXCLUSIVITY
EQ 400MG BASE BOSULIF PF PRISM CV N203341 Oct. 27, 2017 RX TABLET ORAL March 26, 2027 PEDIATRIC EXCLUSIVITY
EQ 500MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL March 26, 2027 PEDIATRIC EXCLUSIVITY
EQ 100MG BASE BOSULIF PF PRISM CV N217729 Sept. 26, 2023 RX CAPSULE ORAL March 26, 2027 PEDIATRIC EXCLUSIVITY
EQ 50MG BASE BOSULIF PF PRISM CV N217729 Sept. 26, 2023 RX CAPSULE ORAL March 26, 2027 PEDIATRIC EXCLUSIVITY
EQ 100MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL Sept. 26, 2030 TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML), NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
EQ 400MG BASE BOSULIF PF PRISM CV N203341 Oct. 27, 2017 RX TABLET ORAL Sept. 26, 2030 TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML), NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
EQ 500MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL Sept. 26, 2030 TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML), NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
EQ 100MG BASE BOSULIF PF PRISM CV N217729 Sept. 26, 2023 RX CAPSULE ORAL Sept. 26, 2030 TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML), NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
EQ 50MG BASE BOSULIF PF PRISM CV N217729 Sept. 26, 2023 RX CAPSULE ORAL Sept. 26, 2030 TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML), NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY
EQ 100MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL March 26, 2031 PEDIATRIC EXCLUSIVITY
EQ 400MG BASE BOSULIF PF PRISM CV N203341 Oct. 27, 2017 RX TABLET ORAL March 26, 2031 PEDIATRIC EXCLUSIVITY
EQ 500MG BASE BOSULIF PF PRISM CV N203341 Sept. 4, 2012 RX TABLET ORAL March 26, 2031 PEDIATRIC EXCLUSIVITY
EQ 100MG BASE BOSULIF PF PRISM CV N217729 Sept. 26, 2023 RX CAPSULE ORAL March 26, 2031 PEDIATRIC EXCLUSIVITY
EQ 50MG BASE BOSULIF PF PRISM CV N217729 Sept. 26, 2023 RX CAPSULE ORAL March 26, 2031 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Proto-oncogene tyrosine-protein kinase Src Kinase INHIBITOR Kd 9 CHEMBL CHEMBL
Tyrosine-protein kinase HCK Kinase INHIBITOR Kd 8.47 CHEMBL CHEMBL
Tyrosine-protein kinase ABL1 Kinase INHIBITOR Kd 10.54 CHEMBL CHEMBL
Tyrosine-protein kinase Lyn Kinase INHIBITOR Kd 8.38 CHEMBL CHEMBL
Mast/stem cell growth factor receptor Kit Kinase Kd 7.14 CHEMBL
Epidermal growth factor receptor Kinase Kd 7.74 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 9.23 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 8.40 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 7.96 CHEMBL
Ephrin type-A receptor 2 Kinase Kd 7.74 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 6 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 5.42 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 6.42 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 5.29 CHEMBL
Receptor tyrosine-protein kinase erbB-2 Kinase Kd 5.60 CHEMBL
Ribosomal protein S6 kinase alpha-3 Kinase Kd 5.92 CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase Kd 5.89 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 6.31 CHEMBL
Rho-associated protein kinase 1 Kinase Kd 6.06 CHEMBL
Focal adhesion kinase 1 Kinase Kd 6.24 CHEMBL
Serine/threonine-protein kinase PLK1 Kinase Kd 5.74 CHEMBL
Receptor tyrosine-protein kinase erbB-4 Kinase Kd 7.59 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 5.51 CHEMBL
Protein kinase C delta type Kinase Kd 5.80 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 5.96 CHEMBL
Rho-associated protein kinase 2 Kinase Kd 6.44 CHEMBL
Tyrosine-protein kinase SYK Kinase Kd 6.54 CHEMBL
Tyrosine-protein kinase CSK Kinase Kd 7.49 CHEMBL
Angiopoietin-1 receptor Kinase Kd 5.41 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 8.05 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit gamma Kinase Kd 5.44 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 5.64 CHEMBL
Hepatocyte growth factor receptor Kinase Kd 5.66 CHEMBL
Cytoplasmic tyrosine-protein kinase BMX Kinase Kd 6.70 CHEMBL
Serine/threonine-protein kinase Nek2 Kinase Kd 5.80 CHEMBL
Ribosomal protein S6 kinase alpha-2 Kinase Kd 5.49 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-1 Kinase Kd 5.41 CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Kinase Kd 6.47 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit alpha Kinase Kd 5.35 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 8.15 CHEMBL
Tyrosine-protein kinase Fer Kinase Kd 6.44 CHEMBL
Protein kinase C epsilon type Kinase Kd 5.62 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 8.82 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 7.57 CHEMBL
Ephrin type-A receptor 4 Kinase Kd 7.74 CHEMBL
Serine/threonine-protein kinase N1 Kinase Kd 5.54 CHEMBL
Protein kinase C theta type Kinase Kd 6.04 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 5.96 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 7.51 CHEMBL
Casein kinase I isoform epsilon Kinase Kd 6.96 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 8.20 CHEMBL
ALK tyrosine kinase receptor Kinase Kd 6.16 CHEMBL
Serine/threonine-protein kinase 36 Kinase Kd 6.24 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 8.24 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 6.46 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 8.85 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 6.22 CHEMBL
Dual specificity protein kinase CLK2 Kinase Kd 5.77 CHEMBL
Dual specificity protein kinase CLK3 Kinase Kd 6.52 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 9.30 CHEMBL
Mitogen-activated protein kinase kinase kinase 4 Kinase Kd 6.96 CHEMBL
Cyclin-G-associated kinase Kinase Kd 8.89 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 5.43 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 7.48 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D Kinase Kd 6.26 CHEMBL
Cyclin-dependent kinase 16 Kinase Kd 5.62 CHEMBL
Serine/threonine-protein kinase 4 Kinase Kd 6.72 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 7.54 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 8.33 CHEMBL
Dual specificity protein kinase CLK4 Kinase Kd 5.49 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 2 Kinase Kd 6.11 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 6.92 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 8.04 CHEMBL
Testis-specific serine/threonine-protein kinase 1 Kinase Kd 5.34 CHEMBL
Cyclin-dependent kinase 15 Kinase Kd 5.80 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 7 Kinase Kd 5.28 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1 Kinase Kd 7.72 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2 Kinase Kd 8 CHEMBL
Tyrosine-protein kinase ITK/TSK Kinase Kd 5.77 CHEMBL
Tyrosine-protein kinase ZAP-70 Kinase Kd 5.80 CHEMBL
Tyrosine-protein kinase BTK Kinase Kd 8.32 CHEMBL
Tyrosine-protein kinase Tec Kinase Kd 5.49 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 7.28 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 5.92 CHEMBL
Tyrosine-protein kinase receptor TYRO3 Kinase Kd 7.21 CHEMBL
Ephrin type-B receptor 2 Kinase Kd 8.08 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 5.92 CHEMBL
Ribosomal protein S6 kinase beta-1 Kinase Kd 6.18 CHEMBL
Serine/threonine-protein kinase N2 Kinase Kd 5.49 CHEMBL
Serine/threonine-protein kinase DCLK3 Kinase Kd 5.27 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 6.43 CHEMBL
Ribosomal protein S6 kinase alpha-6 Kinase Kd 5.57 CHEMBL
NUAK family SNF1-like kinase 2 Kinase Kd 6.66 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 5.35 CHEMBL
Serine/threonine-protein kinase Chk1 Kinase Kd 5.52 CHEMBL
Serine/threonine-protein kinase PAK 3 Kinase Kd 5.24 CHEMBL
Cyclin-dependent kinase 14 Kinase Kd 5.85 CHEMBL
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha Kinase Kd 5.48 CHEMBL
Wee1-like protein kinase Kinase Kd 6.29 CHEMBL
Serine/threonine-protein kinase 25 Kinase Kd 6.05 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 7.10 CHEMBL
Protein-tyrosine kinase 2-beta Kinase Kd 6.41 CHEMBL
Serine/threonine-protein kinase RIO1 Kinase Kd 5.66 CHEMBL
Casein kinase I isoform alpha-like Kinase Kd 5.59 CHEMBL
Casein kinase I isoform delta Kinase Kd 6.62 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 5.54 CHEMBL
Serine/threonine-protein kinase tousled-like 1 Kinase Kd 6.24 CHEMBL
Serine/threonine-protein kinase tousled-like 2 Kinase Kd 5.68 CHEMBL
NT-3 growth factor receptor Kinase Kd 5.47 CHEMBL
Tyrosine-protein kinase TXK Kinase Kd 7.14 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit epsilon Kinase Kd 7.28 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 3 Kinase Kd 5.59 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 7.43 CHEMBL
Serine/threonine-protein kinase NLK Kinase Kd 5.66 CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4 Kinase Kd 6.57 CHEMBL
Serine/threonine-protein kinase RIO3 Kinase Kd 5.80 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 7.54 CHEMBL
Serine/threonine-protein kinase 33 Kinase Kd 7.43 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 6.77 CHEMBL
Ankyrin repeat and protein kinase domain-containing protein 1 Kinase Kd 5.68 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 6.85 CHEMBL
Myotonin-protein kinase Kinase Kd 7.04 CHEMBL
Leukocyte tyrosine kinase receptor Kinase Kd 5.52 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 7.82 CHEMBL
NUAK family SNF1-like kinase 1 Kinase Kd 5.23 CHEMBL
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase Kinase Kd 6.46 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 8.29 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 8.48 CHEMBL
Bone morphogenetic protein receptor type-2 Kinase Kd 6.24 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 8.09 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4 Kinase Kd 5.59 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 6 Kinase Kd 5.89 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 6.96 CHEMBL
Mitogen-activated protein kinase kinase kinase 9 Kinase Kd 5.57 CHEMBL
Mitogen-activated protein kinase kinase kinase 11 Kinase Kd 5.57 CHEMBL
Serine/threonine-protein kinase 24 Kinase Kd 6.42 CHEMBL
Citron Rho-interacting kinase Kinase Kd 5.62 CHEMBL
Myosin-IIIa Kinase Kd 5.21 CHEMBL
Myosin-IIIb Kinase Kd 5.64 CHEMBL
Serine/threonine-protein kinase PAK 1 Kinase Kd 5.64 CHEMBL
Serine/threonine-protein kinase PAK 2 Kinase Kd 5.72 CHEMBL
Serine/threonine-protein kinase SIK1 Kinase Kd 7.52 CHEMBL
Tyrosine-protein kinase Srms Kinase Kd 7 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 5.64 CHEMBL
Ephrin type-B receptor 3 Kinase Kd 6.68 CHEMBL
Mitogen-activated protein kinase 7 Kinase Kd 5.64 CHEMBL
Serine/threonine-protein kinase D3 Kinase Kd 5.34 CHEMBL
Tyrosine-protein kinase Fes/Fps Kinase Kd 6.48 CHEMBL
Casein kinase I isoform alpha Kinase Kd 6.55 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 8.51 CHEMBL
Misshapen-like kinase 1 Kinase Kd 8.49 CHEMBL
Serine/threonine-protein kinase TBK1 Kinase Kd 6.60 CHEMBL
Interleukin-1 receptor-associated kinase 4 Kinase Kd 6.44 CHEMBL
Serine/threonine-protein kinase Chk2 Kinase Kd 6.92 CHEMBL
Protein delta homolog 1 Membrane other Kd 6.17 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 5.52 CHEMBL
G protein-coupled receptor kinase 4 Kinase Kd 5.31 CHEMBL
G protein-coupled receptor kinase 7 Kinase Kd 5.77 CHEMBL
Homeodomain-interacting protein kinase 2 Kinase Kd 5.72 CHEMBL
Homeodomain-interacting protein kinase 3 Kinase Kd 5.49 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 6.89 CHEMBL
Hormonally up-regulated neu tumor-associated kinase Kinase Kd 5.30 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 6.22 CHEMBL
Mitogen-activated protein kinase kinase kinase 13 Kinase Kd 6.32 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 7.52 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 7.27 CHEMBL
Microtubule-associated serine/threonine-protein kinase 1 Kinase Kd 6.46 CHEMBL
Serine/threonine-protein kinase NIM1 Kinase Kd 5.82 CHEMBL
SRSF protein kinase 3 Kinase Kd 5.41 CHEMBL
STE20/SPS1-related proline-alanine-rich protein kinase Kinase Kd 5.43 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 7 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 5.89 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 6.47 CHEMBL
Serine/threonine-protein kinase ULK1 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase ULK2 Kinase Kd 6.35 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 6.34 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 7.80 CHEMBL
Homeodomain-interacting protein kinase 1 Kinase Kd 6.28 CHEMBL
Serine/threonine-protein kinase PLK2 Kinase Kd 6.02 CHEMBL
Serine/threonine-protein kinase 35 Kinase Kd 8.70 CHEMBL
Megakaryocyte-associated tyrosine-protein kinase Kinase Kd 5.24 CHEMBL
Receptor tyrosine-protein kinase erbB-3 Kinase Kd 9.11 CHEMBL
Mitogen-activated protein kinase kinase kinase 1 Kinase Kd 5.36 CHEMBL
Serine/threonine-protein kinase SIK3 Kinase Kd 7.19 CHEMBL
Wee1-like protein kinase 2 Kinase Kd 7.03 CHEMBL
Serine/threonine-protein kinase 32A Kinase Kd 5.74 CHEMBL
Peripheral plasma membrane protein CASK Kinase Kd 6.08 CHEMBL
Serine/threonine-protein kinase VRK2 Kinase Kd 6.15 CHEMBL
Mitogen-activated protein kinase kinase kinase 12 Kinase Kd 6.17 CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 1 Kinase Kd 6.20 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 5.72 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 8.09 CHEMBL
Serine/threonine-protein kinase Nek11 Kinase Kd 6.19 CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2 Kinase Kd 6.30 CHEMBL
Dual serine/threonine and tyrosine protein kinase Kinase Kd 6.42 CHEMBL
NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) Kinase IC50 6.82 CHEMBL
Tyrosine-protein kinase ABL Kinase IC50 8.96 CHEMBL
Bcr/Abl fusion protein Kinase IC50 7.70 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 5.92 CHEMBL
Uncharacterized protein FLJ45252 Unclassified Kd 5.87 CHEMBL
Macrophage-stimulating protein receptor Kinase Kd 5.20 CHEMBL
ATP-binding cassette sub-family G member 2 Transporter IC50 5.70 CHEMBL
Platelet-derived growth factor receptor beta Kinase Kd 6.70 CHEMBL
Tyrosine-protein kinase Blk Kinase IC50 8.14 CHEMBL
Serine/threonine-protein kinase PknB Kinase Kd 5.26 CHEMBL

External reference:

IDSource
4031718 VUID
N0000185728 NUI
D03252 KEGG_DRUG
4031718 VANDF
C1831731 UMLSCUI
CHEBI:39112 CHEBI
DB8 PDB_CHEM_ID
CHEMBL288441 ChEMBL_ID
CHEMBL2095206 ChEMBL_ID
DB06616 DRUGBANK_ID
C471992 MESH_SUPPLEMENTAL_RECORD_UI
5710 IUPHAR_LIGAND_ID
8715 INN_ID
918639-08-4 SECONDARY_CAS_RN
5018V4AEZ0 UNII
5328940 PUBCHEM_CID
1307619 RXNORM
192772 MMSL
28803 MMSL
d07901 MMSL
014636 NDDF
703128001 SNOMEDCT_US
703585009 SNOMEDCT_US
703586005 SNOMEDCT_US
5018V4AEZ0 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
BOSULIF HUMAN PRESCRIPTION DRUG LABEL 1 0069-0135 TABLET, FILM COATED 100 mg ORAL NDA 33 sections
BOSULIF HUMAN PRESCRIPTION DRUG LABEL 1 0069-0136 TABLET, FILM COATED 500 mg ORAL NDA 33 sections
BOSULIF HUMAN PRESCRIPTION DRUG LABEL 1 0069-0193 TABLET, FILM COATED 400 mg ORAL NDA 33 sections
BOSULIF HUMAN PRESCRIPTION DRUG LABEL 1 0069-0504 CAPSULE 50 mg ORAL NDA 33 sections
BOSULIF HUMAN PRESCRIPTION DRUG LABEL 1 0069-1014 CAPSULE 100 mg ORAL NDA 33 sections
Bosutinib Human Prescription Drug Label 1 46708-311 TABLET, FILM COATED 100 mg ORAL ANDA 27 sections
Bosutinib Human Prescription Drug Label 1 46708-312 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
Bosutinib Human Prescription Drug Label 1 62332-311 TABLET, FILM COATED 100 mg ORAL ANDA 27 sections
Bosutinib Human Prescription Drug Label 1 62332-312 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
BOSULIF HUMAN PRESCRIPTION DRUG LABEL 1 63539-117 TABLET, FILM COATED 100 mg ORAL NDA 33 sections
BOSULIF HUMAN PRESCRIPTION DRUG LABEL 1 63539-193 TABLET, FILM COATED 400 mg ORAL NDA 33 sections
Bosutinib Human Prescription Drug Label 1 75907-405 TABLET, FILM COATED 400 mg ORAL ANDA 26 sections